Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. It develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. It operates a pipeline of theranostic radiopharmaceutical product candidates with a focus on urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. Its segments include commercial, product development, medical technologies, and manufacturing services. Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX101, TLX300, TLX66, TLX66-CDx, and TLX090, among others.

Employees

423

Sector

Biotechnology & Medical Research

Calendar

21/08 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
11/25/11	24.36 $	-0.47%	87,719
10/25/10	24.47 $	-3.62%	12,34,472
09/25/09	25.39 $	+5.62%	18,88,127
08/25/08	24.04 $	-0.04%	7,70,153
07/25/07	24.05 $	-0.58%	4,41,596

Delayed Quote Australian S.E., July 11, 2025 at 05:59 am IST

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG MSCI

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

24.47AUD

Average target price

32.05AUD

Spread / Average Target

+30.97%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed Australian S.E. Other stock markets 05:59:27 11/07/2025 am IST			5-day change	1st Jan Change
24.36 ^AUD	-0.47%		+1.84%	-0.89%

10/07	Telix Pharmaceuticals Limited Receives Permanent HCPCS Code for Gozellix from U.S. Centers for Medicare & Medicaid Services	CI
09/07	Telix's Prostate Cancer Imaging Agent Gozellix Secures US Reimbursement Code, Shares Up 6%	MT

Capitalization	828.02Cr 543.46Cr 464.99Cr 433.28Cr 400.69Cr 743.74Cr 47TCr 5.18TCr 1.98TCr 22TCr 2.04TCr 2TCr 80TCr	P/E ratio 2025 *	44.8x	P/E ratio 2026 *	29.2x
Enterprise value	842.44Cr 552.93Cr 473.08Cr 440.83Cr 407.66Cr 756.69Cr 47TCr 5.27TCr 2.01TCr 22TCr 2.07TCr 2.03TCr 81TCr	EV / Sales 2025 *	6.61x	EV / Sales 2026 *	5.11x
Free-Float	58.65%	Yield 2025 *	-	Yield 2026 *	-

Telix Pharmaceuticals Limited Receives Permanent HCPCS Code for Gozellix from U.S. Centers for Medicare & Medicaid Services	10/07	CI
Telix's Prostate Cancer Imaging Agent Gozellix Secures US Reimbursement Code, Shares Up 6%	09/07	MT
HC Wainwright Initiates Telix Pharmaceuticals at Buy With $23 Price Target	03/07	MT
Telix Manufacturing Solutions Belgium Delivers First GMP-Grade Commercial Doses	25/06	CI
Telix Says Illuccix Wins FDA Approval for Patient Selection for Pre-Taxane Radioligand Therapy	23/06	MT
Telix Pharmaceuticals Limited Approves in U.S. for Patient Selection for Pre-Taxane RLT	23/06	CI
Telix Shares Fall After Launch of Radiochemistry Platform, Belgium University Agreement	23/06	MT
Telix Precision Medicine Announces AlFluor Radiochemistry Platform	20/06	CI
Telix Pharmaceuticals Limited Announces Prostate Cancer PSMA-PET Imaging Agent Approved in Greece	13/06	CI
Telix Pharmaceuticals Limited - Analyst/Investor Day	12/06
Telix Pharmaceuticals Announces Gozellix Now Available Nationally In U.S.	11/06	RE
Telix Launches New Prostate Cancer Imaging Agent, Gozellix, in U.S	11/06	CI
Telix Opens Manufacturing Facility in Japan	06/06	MT

HC Wainwright Initiates Telix Pharmaceuticals at Buy With $23 Price Target	03/07	MT
Wedbush Initiates Telix Pharmaceuticals at Outperform With $22 Price Target	05/06	MT
UBS Adjusts Price Target on Telix Pharmaceuticals to $22 From $21, Keeps Buy Rating	27/01	MT
Bell Potter Downgrades Telix Pharmaceuticals to Hold From Buy; Price Target is AU$21.30	23/24/23	MT
Jarden Research Adjusts Telix Pharmaceuticals' Price Target to AU$22.55 From AU$22.49, Keeps at Buy	30/24/30	MT

Telix Pharmaceuticals Limited Share Price

Equities

TLX

AU000000TLX2

Biotechnology & Medical Research

Valuation: Telix Pharmaceuticals Limited

Chart: Telix Pharmaceuticals Limited

Latest news: Telix Pharmaceuticals Limited

Last Transcript: Telix Pharmaceuticals Limited

Analysts' recommendations: Telix Pharmaceuticals Limited

Press Releases: Telix Pharmaceuticals Limited

News in other languages: Telix Pharmaceuticals Limited

Quotes and Performance

Course Extremes

Managers and Directors: Telix Pharmaceuticals Limited

ETFs: Telix Pharmaceuticals Limited

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Gozellix Receives Permanent HCPCS Code	10/07	AQ
Telix Pharmaceuticals : Application for quotation of securities - TLX	09/07	PU
Telix Pharmaceuticals : Manufacturing Solutions Belgium Delivers First GMP-Grade Commercial Doses	25/06	PU
Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT	23/06	AQ
Telix Precision Medicine Announces AlFluor Radiochemistry Platform	20/06	AQ

Telix Pharmaceuticals Limited schließt die Übernahme von ARTMS, Inc. ab.	11/24/11
Telix Pharmaceuticals Limited completa la adquisición de ARTMS Inc.	11/24/11
Mauna Kea: la biotech Telix acquiert 19% du capital pour 6 millions d'euros	13/23/13
En Direct des Marchés : Airbus, TotalEnergies, Eramet, Valneva, BAE Systems, Novo Nordisk, Solvay...	13/23/13
Mauna Kea Technologies et Telix Pharmaceuticals entendent renforcer leur partenariat dans le domaine de la chirurgie uro-oncologique	13/23/13

1 day	-0.33%
1 week	+1.84%
Current month	-0.12%
1 month	-6.12%
3 months	-8.24%
6 months	+1.67%
Current year	-0.89%

1 week	23.61	25.87
1 month	22.76	26.25
Current year	21.4	31.97
1 year	17.03	31.97
3 years	4.37	31.97
5 years	1.24	31.97
10 years	0.46	31.97

Manager	Title	Age	Since
Christian Behrenbruch CEO	Chief Executive Officer	50	03/01/2017
Darren Smith DFI	Director of Finance/CFO	59	31/07/2022
Michael Wheatcroft CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Christian Behrenbruch BRD	Director/Board Member	50	03/01/2017
Mark Nelson BRD	Director/Board Member	65	17/09/2017
Jann Skinner BRD	Director/Board Member	67	19/06/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
TELIX PHARMACEUTICALS LIMITED	-0.47%	+1.84%	+38.77%	+346.88%	560.88Cr
LONZA GROUP AG	+1.21%	+1.90%	+12.84%	+0.60%	4.99TCr
BEONE MEDICINES LTD.	-0.90%	+3.22%	+73.51%	+34.25%	3.03TCr
CELLTRION, INC.	+1.42%	+5.74%	+4.18%	+11.14%	2.83TCr
IQVIA HOLDINGS INC.	+2.17%	+0.53%	-22.30%	-24.53%	2.8TCr
EUROFINS SCIENTIFIC SE	+1.54%	-0.07%	+29.84%	-21.96%	1.25TCr
ICON PUBLIC LIMITED COMPANY	+1.02%	+1.31%	-53.73%	-30.23%	1.2TCr
ASCENDIS PHARMA A/S	+0.44%	+1.33%	+28.51%	+88.54%	1.06TCr
QIAGEN N.V.	+1.23%	-0.19%	+17.83%	-5.21%	1.04TCr
TEMPUS AI, INC.	+2.04%	-2.25%	+70.29%	-	1.01TCr
Average	+0.85%	-0.80%	+19.97%	+44.39%	1.98TCr
Weighted average by Cap.	+0.95%	-0.66%	+17.74%	+15.41%

	2025 *	2026 *
Net sales	127.4Cr 84Cr 72Cr 67Cr 62Cr 114.43Cr 7.17TCr 797.09Cr 304.41Cr 3.35TCr 313.57Cr 307.14Cr 12TCr	161.67Cr 106.11Cr 91Cr 85Cr 78Cr 145.21Cr 9.1TCr 1.01TCr 386.3Cr 4.25TCr 397.92Cr 389.76Cr 16TCr
Net income	21Cr 14Cr 12Cr 11Cr 10Cr 19Cr 1.21TCr 134.28Cr 51Cr 564.39Cr 53Cr 52Cr 2.06TCr	33Cr 22Cr 19Cr 17Cr 16Cr 30Cr 1.87TCr 208.4Cr 80Cr 875.9Cr 82Cr 80Cr 3.2TCr
Net Debt	14Cr 9.46Cr 8.1Cr 7.54Cr 6.98Cr 13Cr 811.35Cr 90Cr 34Cr 379.11Cr 35Cr 35Cr 1.39TCr	-2.49Cr -1.64Cr -1.4Cr -1.3Cr -1.21Cr -2.24Cr -140.22Cr -16Cr -5.95Cr -66Cr -6.13Cr -6.01Cr -239.47Cr